top of page

Mental Illness

Adolescent Exposure to Chronic Delta-9-Tetrahydrocannabinol Blocks Opiate Dependence in Maternally Deprived Rats

β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice

Brain CB2 Receptors: Implications for Neuropsychiatric Disorders

Cannabidiol reverses the mCPP-induced increase in marble-burying behavior

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug

Cannabidiol as a potential treatment for psychosis

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

Cannabidiol for the treatment of psychosis in Parkinson's disease

Cannabidiol, neuroprotection and neuropsychiatric disorders

Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential

Cortical GAD67 deficiency results in lower cannabinoid 1 receptor mRNA expression: Implications for schizophrenia

Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain

Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis

Long term marijuana users seeking medical cannabis in California (2001–2007): demographics, social characteristics, patterns of cannabis and other drug use of 4117 applicants

Motor effects of delta 9 THC in cerebellar Lurcher mutant mice

Multiple mechanisms involved in the large-spectrum therapeutic potential of
cannabidiol in psychiatric disorders

Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report

Cannabinoid CB1 receptors in the dorsal hippocampus and prelimbic medial prefrontal cortex modulate anxiety-like behavior in rats: additional evidence

The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system

The Development of Cannabidiol as a Psychiatric Therapeutic: A Review of Its
Antipsychotic Efficacy and Possible Underlying Pharmacodynamic Mechanisms

The development of cannabidiol as a psychiatric therapeutic: a review of its antipsychotic efficacy and possible underlying pharmacodynamic mechanisms.

Therapeutical use of the cannabinoids in psychiatry

Cannabidiol, a Nonpsychotropic Component of Cannabis, Inhibits Cue-Induced Heroin Seeking and Normalizes Discrete Mesolimbic Neuronal Disturbances

Cannabidiol Reverses MK-801-Induced Disruption of Prepulse Inhibition in Mice

Cannabis as a substitute for alcohol and other drugs

CB1 cannabinoid receptor stimulation during adolescence impairs the maturation of GABA function in the adult rat prefrontal cortex

Distinct Neurobehavioural Effects of Cannabidiol in Transmembrane Domain Neuregulin 1 Mutant Mice

Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance

Joint Effects: A Pilot Investigation of the Impact of Bipolar Disorder and Marijuana
Use on Cognitive Function and Mood

Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology

Cannabinoid CB1 receptors in the dorsal hippocampus and prelimbic medial prefrontal cortex modulate anxiety-like behavior in rats: Additional evidence

The endocannabinoid system and emotional processing: A pharmacological fMRI study with Δ9-tetrahydrocannabinol

Migraine

Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model

Clinical Endocannabinoid Deficiency (CECD): Can this Concept Explain Therapeutic Benefits of Cannabis in Migraine, Fibromyalgia, Irritable Bowel Syndrome and other
Treatment-Resistant Conditions?

Clinical endocannabinoid deficiency (CECD) revisited: Can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It’s Been . . .

Effects of anandamide in migraine: data from an animal model

Endocannabinoids in the Brainstem Modulate Dural Trigeminovascular Nociceptive Traffic via CB1 and “Triptan” Receptors: Implications in Migraine

Endocannabinoid System and Migraine Pain: An Update

MTHFR Gene Mutation

Anti-inflammatory effects of the cannabidiol derivative dimethylheptyl-cannabidiol – studies in BV-2 microglia and encephalitogenic T cells

Cannabidiol affects the expression of genes involved in zinc homeostasis in BV-2
microglial cells

Cannabidiol Post-Treatment Alleviates Rat Epileptic-Related Behaviors and Activates Hippocampal Cell Autophagy Pathway Along with Antioxidant Defense in Chronic Phase of Pilocarpine-Induced Seizure

Cannabidiol Protects against Doxorubicin-Induced Cardiomyopathy by Modulating Mitochondrial Function and Biogenesis

Mechanisms of cannabidiol neuroprotection in hypoxiceischemic newborn pigs:
Role of 5HT1A and CB2 receptors

Protective effect of cannabidiol against cadmium hepatotoxicity in rats

Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats

Multiple Sclerosis

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors

Mitochondria: a possible nexus for the regulation of energy homeostasis by the endocannabinoid system?

Cannabinoid Modulation of Neuroinflammatory Disorders

Cannabinoids and multiple sclerosis

Cannabinoids control spasticity and tremor in a multiple sclerosis model

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up

Cannabinoids in the management of spasticity associated with multiple sclerosis

Clinical experiences with cannabinoids in spasticity management in multiple sclerosis

Effects of cannabis on cognitive function in patients with multiple sclerosis

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study

Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice

The cannabinoids: An overview.  Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection

Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis: A Double-Blind, Placebo Controlled, Crossover Study

Randomized, controlled trial of cannabisbased medicine in central pain in multiple sclerosis

Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation

Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial

Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity

THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms

The effect of cannabis on tremor in patients with multiple sclerosis

The Endocannabinoid System Is Dysregulated in Multiple Sclerosis and in Experimental Autoimmune Encephalomyelitis

Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis

Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review

bottom of page